The preclinical profile of brexpiprazole: What is its clinical relevance for the treatment of psychiatric disorders?

Expert Review of Neurotherapeutics

Volumn 15, Issue 10, 2015, Pages 1219-1229

  Citrome, Leslie ^a   Stensbøl, Tine Bryan ^b   Maeda, Kenji ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b H LUNDBECK A S   (Denmark)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

behavioral models; brexpiprazole; pharmacology; preclinical; receptor binding

Indexed keywords

ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ARIPIPRAZOLE; BREXPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; LURASIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTIDEPRESSANT ACTIVITY; BINDING AFFINITY; CATALEPSY; COGNITION; DEPRESSION; DRUG RECEPTOR BINDING; HUMAN; HYPERPROLACTINEMIA; INTRINSIC ACTIVITY; MENTAL DISEASE; NERVE FIBER GROWTH; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PARTIAL AGONISM; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY; ANIMAL; MENTAL DISORDERS; PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MENTAL DISORDERS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 84942919841     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1086269     Document Type: Review

References (80)

1. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3: 353-9
2. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-62
3. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013; 10: e1001403
4. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217-19
5. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012; 212: 27-52
6. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 2005; 427: 43-6
7. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014; 2014: 656370
8. Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 2012; 13: 1572-86
9. Bolonna AA, Kerwin RW. Partial agonism and schizophrenia. Br J Psychiatry 2005; 186: 7-10
10. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005; 6: 2091-101
11. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 2008; 200: 317-31
12. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57 (Suppl 11): 40-5
13. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007; 8: 539-54
14. Stip E, Touriman V. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther 2010; 32: S3-20
15. Maeda K, Stensbøl TB, Hentzer M, et al. In vitro pharmacological profile of brexpiprazole, a novel serotonin-dopamine activity modulator. Society of Biological Psychiatry 69th Annual Meeting 2014. P412
16. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 589-604
17. Amada N, Maeda K, Akazawa H, et al. Brexpiprazole, a novel serotonin-dopamine activity modulator: in vivo evaluation of its antipsychotic-like profile. Society of Biological Psychiatry 69th Annual Meeting 2014. P410
18. Oosterhof C, El Mansari M, Blier P. In vivo electrophysiological characterization of the acute effects of brexpiprazole on serotonin, dopamine and norepinephrine neuronal activities. Society of Biological Psychiatry 69th Annual Meeting 2014. P1373
19. Oosterhof CA, El MM, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther 2014; 351: 585-95
20. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010; 333: 328-40
21. Mørk A, Nielsen V, Pehrson A, et al. Effects of brexpiprazole on receptor occupancies and extracellular levels of neurotransmitters in the rat brain. Society of Biological Psychiatry 69th Annual Meeting 2014. P407
22. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: Antipsychotic-like and pro-cognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 605-14
23. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277: 137-43
24. Wolfarth S, Ossowska K. Can the supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 799-840
25. Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol 2002; 54: 299-312
26. Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 336-9
27. Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010; 128: 419-32
28. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 2011; 213: 289-305
29. Lerdrup L, Plath N, Nielsen V, et al. Pro-cognitive effect of brexpiprazole in the subchronic phencyclidine rat model. Society of Biological Psychiatry 69th Annual Meeting 2014. P406
30. Yoshimi N, Fujita Y, Ohgi Y, et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT receptors. Pharmacol Biochem Behav 2014; 124C: 245-9
31. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol 2015; 25: 356-64
32. Connolly KR, Thase ME. If at first you dont succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71: 43-64
33. Hirose T, Maeda K, Stensbøl TB, Kikuchi T. Synergistic effects of brexpiprazole with SSRI/SNRI/diazepam on forced swim test and marble burying behaviour in mice. Biol Psychiatry 2014; 75 (9 Suppl 1): 132S
34. Njunge K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991; 38: 63-7
35. Lu XH, Dwyer DS. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 2005; 27: 43-64
36. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358-403
37. Molteni R, Calabrese F, Racagni G, et al. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009; 124: 74-85
38. Williams B, Dwyer DS. Structure-based discovery of low molecular weight compounds that stimulate neurite outgrowth and substitute for nerve growth factor. J Neurochem 2009; 110: 1876-84
39. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008; 3: e2558
40. Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1656-9
41. Hashimoto K, Ishima T. A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation [corrected] factor eIF4AI. PLoS One 2010; 5: e15430
42. Minase T, Ishima T, Itoh K, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by the ROCK inhibitor Y-27632: a possible role of IP(3) receptors. Eur J Pharmacol 2010; 648: 67-73
43. Itoh K, Ishima T, Kehler J, Hashimoto K. Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma, IP3 receptors. Brain Res 2011; 1377: 32-40
44. Ishima T, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors. PLoS ONE 2012; 7: e37989
45. Ishima T, Futamura T, Ohgi Y, et al. Potentiation of neurite outgrowth by the novel antipsychotic drug brexpiprazole: A role for serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 2015; 25: 505-11
46. Citrome L. Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc) 2015; 51: 397-414
47. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009; 10: 1917-28
48. Rexulti Prescribing Information. Otsuka Pharmaceutical Co Ltd. 2015. Available from: www.otsuka-us.com/products/Documents/Rexulti.PI.pdf. [Last accessed 12 August 2015]
49. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015; 69: 978-97
50. Abilify prescribing information. Otsuka Pharmaceutical Co Ltd. 2014. Available from: www.otsuka-us.com/Documents/Abilify.PI.pdf. [Last accessed 12 August 2015]
51. Abilify Maintena Prescribing Information. Otsuka Pharmaceutical Co Ltd. 2014. Available from: www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf. [Last accessed 10 December 2014]
52. Stahl SM. Role of alpha1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr 2013; 18: 285-8
53. Green B. Prazosin in the treatment of PTSD. J Psychiatr Pract 2014; 20: 253-9
54. Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009; 17: 744-51
55. Drouin C, Darracq L, Trovero F, et al. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 2002; 22: 2873-84
56. Haddjeri N, Blier P, de MC. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 20-9
57. Brosda J, Jantschak F, Pertz HH. α2-Adrenoceptors are targets for antipsychotic drugs. Psychopharmacology (Berl) 2014; 231: 801-12
58. Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study. Biol Psychiatry 2015; 77: 203S
59. Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; Epub ahead of print
60. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015; 164: 127-35
61. Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf 2014; 13: 1187-97
62. Peuskens J, Pani L, Detraux J, De HM. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28: 421-53
63. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010; 11: 802-12
64. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011; 216: 451-73
65. Rogóz Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep 2013; 65: 1535-44
66. Thase ME, Youakim JM, Skuban M, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; Epub ahead of print
67. Thase ME, Youakim JM, Skuban M, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; Epub ahead of print
68. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013; 9: 193-206
69. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013; 27: 879-911
70. Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther 2013; 30: 102-13
71. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther 2013; 30: 114-26
72. Citrome L. New treatment targets to improve symptoms in schizophrenia. J Clin Psychiatry 2014; 75 (8): e22
73. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003; 28: 1400-11
74. Lurasidone Prescribing Information. Sunovion Pharmaceuticals Inc. 2013. Available from: www.latuda.com/LatudaPrescribingInformation.pdf. [Last accessed 28 October 2014]
75. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334: 171-81
76. Seroquel XR prescribing information. AstraZeneca Pharmaceuticals Inc. 2013. Available from: www1.astrazeneca-us.com/pi/seroquelxr.pdf. [Last accessed 10 December 2014]
77. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999; 4: 418-28
78. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol 2003; 28: 519-26
79. PDSP Ki database. 2014. Available from: pdsp.med.unc.edu/pdsp.php. [Last accessed 21 October 2014]
80. Schotte A, Janssen PF, Bonaventure P, Leysen JE. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem J 1996; 28: 791-9